Wolfe starts AbbVie at Outperform, says valuation an attractive entry point
Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...
JPMorgan trims AbbVie target, removes from Analyst Focus List
JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...
Global Respiratory Disease Testing Market to Grow at a CAGR of ~4% by 2030 | DelveInsight
DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual ...
Quotidianosanità.it14d
Epatite C. Nuovi farmaci “interferon free” solo per pochi. Aifa fissa i criteri per l’accesso. Ecco chi potrà accedervi e a chi rivolgersi
Tale accesso per uso nominale è aperto a tutti i pazienti, per le cui richieste di trattamento i centri non inclusi nella lista allegata potranno contattare la Direzione Medica di AbbVie srl”.
Nasdaq14d
Is AbbVie (NYSE:ABBV) Stock a Buy After Its Dividend Hike?
Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...
Nasdaq14d
AbbVie Reaches Analyst Target Price
In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $202.46, changing hands for $203.87/share. When a stock reaches the target an ...
Morningstar16d
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics ...
Investing17d
AbbVie (ABBV) Earnings Dates & Reports
View upcoming earnings forecasts and in-depth analysis of company forecasts.
The Sunday Business Post17d
AbbVie lifts profit outlook as inflammatory drugs beat estimates
LATEST NEWS 07:15 Live News: Asian markets update; Fianna Fáil, Fine Gael and Sinn Féin’s housing plans rated 05:00 Comer brothers told to change plans for apartments next to Maynooth church 05:00 ...
Benzinga.com21d
Forecasting The Future: 11 Analyst Projections For AbbVie
In the last three months, 11 analysts have published ratings on AbbVie ABBV, offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...
FierceBiotech21d
AbbVie makes Richter richer, paying $25M to form discovery pact with Vraylar originator
AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 million upfront to form a new drug discovery pact with Gedeon Richter.
PharmTech23d
FDA Approves AbbVie Therapy for Adults with Advanced Parkinson’s Disease
FDA has approved the AbbVie treatment Vyalev (foscarbidopa and foslevodopa) for use in adult patients with advanced Parkinson’s disease, AbbVie announced in a press release on Oct. 17, 2024 (1). The ...